Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

Holger W. Auner(University Hospital of Lausanne), Gordon Cook(University of Leeds), Jessica Kendall(University of Leeds), Mark Cook(Université Paris Cité), Sarah Brown(University of Leeds), Martin Kaiser(Royal Marsden NHS Foundation Trust), Katrina Walker(University of Leeds), Sadie Roberts(University of Leeds), David Meads(University of Leeds), Christopher Parrish(Children's Medical Center), Gareth J. Morgan(Hywel Dda University Health Board), Bryony Dawkins(University of Leeds)
Blood Cancer Journal
April 1, 2022
10.1038/s41408-022-00626-4
Cited by 15

Related Papers

The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3.1k
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k